Top CV, COVID-19 news: Panel on evolving knowledge, safety of RAAS antagonists and more

Healio and Cardiology Today present the most-read articles on COVID-19 and the heart. Our readers were interested in the safety of RAAS antagonists in COVID-19, resuming elective surgeries, returning to exercise after infection and more.

COVID-19 and the heart: Knowledge ‘evolving by the hour’

Understanding COVID-19 and SARS-CoV-2 is imperative for the cardiology community, and beyond. To that end, Cardiology Today and Healio convened a panel of experts from a variety of backgrounds, including basic science, virology, vascular biology, pathology, HF, arrhythmia disorders, cardio-oncology and cardiac intensive care, to discuss the CV implications of COVID-19 and the virus that causes it. Read more

Evidence suggests no COVID-19-related harm from RAAS antagonists

Because the virus that causes COVID-19 acts through the ACE2 receptor, there was concern that use of renin-angiotensin-aldosterone system antagonists such as ACE inhibitors and angiotensin receptor blockers, which are used to treat hypertension, HF and other CV conditions, might predispose people to COVID-19 or worsen its effects. But emerging data suggest that concern is unfounded. Read more

Gradual return to exercise after COVID-19 requires ‘cautious approach’

In patients with COVID-19, the severity of the disease and the possibility of CV involvement should be taken into account when considering a return to intense exercise training and competition. Read more

Review identifies possible mechanisms for elevated troponin, cardiac injury in COVID-19

No mechanism has been definitively proved as the cause for elevated troponin in patients with COVID-19, but researchers suggested that risk factors such as myocarditis, ACE2 downregulation, type 2 MI and cytokine storm may be associated with myocardial injury in those with the disease. Read more

Ultrasound systems net clearance for management of lung, CV complications of COVID-19

Philips announced that it has received 510(k) clearance from the FDA to market its ultrasound solutions portfolio for the management of lung and cardiac complications associated with COVID-19. Read more

Right ventricular longitudinal strain may predict mortality in COVID-19

Right ventricular longitudinal strain predicted higher mortality in patients with COVID-19, according to a study published in JACC: Cardiovascular Imaging. Read more

Ambulatory telemetry monitors may help arrhythmia management in COVID-19

Ambulatory telemetry monitors for patients with COVID-19 being treated with hydroxychloroquine and/or azithromycin provided real-time alerts to electrophysiologists and may improve their ability to monitor QTc changes and arrhythmias, reduce the need for serial ECGs and better allocate resources, researchers reported. Read more

Updated clearance for AI-based software may aid cardiac diagnoses in COVID-19

Caption Health announced that the FDA issued an updated clearance for its artificial intelligence-guided image acquisition system for use with cardiac ultrasound, which has the potential to minimize caregiver contact with patients with known or suspected COVID-19. Read more

‘New era of close collaboration’ key when reintroducing elective CV procedures during COVID-19 pandemic

Once the COVID-19 pandemic starts to subside, gradual reintroduction and collaborative approaches are important to continue the care of patients with untreated CVD, according to guidance from 15 North American cardiology societies. Read more

ACC: New module to collect data on CV complications of COVID-19

Using the National Cardiovascular Data Registry Chest Pain-MI and CathPCI registries, the American College of Cardiology will begin collecting data with the aim of discerning the relationship between the COVID-19 and heart disease. Read more

Healio and Cardiology Today present the most-read articles on COVID-19 and the heart. Our readers were interested in the safety of RAAS antagonists in COVID-19, resuming elective surgeries, returning to exercise after infection and more.

COVID-19 and the heart: Knowledge ‘evolving by the hour’

Understanding COVID-19 and SARS-CoV-2 is imperative for the cardiology community, and beyond. To that end, Cardiology Today and Healio convened a panel of experts from a variety of backgrounds, including basic science, virology, vascular biology, pathology, HF, arrhythmia disorders, cardio-oncology and cardiac intensive care, to discuss the CV implications of COVID-19 and the virus that causes it. Read more

Evidence suggests no COVID-19-related harm from RAAS antagonists

Because the virus that causes COVID-19 acts through the ACE2 receptor, there was concern that use of renin-angiotensin-aldosterone system antagonists such as ACE inhibitors and angiotensin receptor blockers, which are used to treat hypertension, HF and other CV conditions, might predispose people to COVID-19 or worsen its effects. But emerging data suggest that concern is unfounded. Read more

Gradual return to exercise after COVID-19 requires ‘cautious approach’

In patients with COVID-19, the severity of the disease and the possibility of CV involvement should be taken into account when considering a return to intense exercise training and competition. Read more

Review identifies possible mechanisms for elevated troponin, cardiac injury in COVID-19

No mechanism has been definitively proved as the cause for elevated troponin in patients with COVID-19, but researchers suggested that risk factors such as myocarditis, ACE2 downregulation, type 2 MI and cytokine storm may be associated with myocardial injury in those with the disease. Read more

Ultrasound systems net clearance for management of lung, CV complications of COVID-19

Philips announced that it has received 510(k) clearance from the FDA to market its ultrasound solutions portfolio for the management of lung and cardiac complications associated with COVID-19. Read more

Right ventricular longitudinal strain may predict mortality in COVID-19

Right ventricular longitudinal strain predicted higher mortality in patients with COVID-19, according to a study published in JACC: Cardiovascular Imaging. Read more

Ambulatory telemetry monitors may help arrhythmia management in COVID-19

Ambulatory telemetry monitors for patients with COVID-19 being treated with hydroxychloroquine and/or azithromycin provided real-time alerts to electrophysiologists and may improve their ability to monitor QTc changes and arrhythmias, reduce the need for serial ECGs and better allocate resources, researchers reported. Read more

Updated clearance for AI-based software may aid cardiac diagnoses in COVID-19

Caption Health announced that the FDA issued an updated clearance for its artificial intelligence-guided image acquisition system for use with cardiac ultrasound, which has the potential to minimize caregiver contact with patients with known or suspected COVID-19. Read more

‘New era of close collaboration’ key when reintroducing elective CV procedures during COVID-19 pandemic

Once the COVID-19 pandemic starts to subside, gradual reintroduction and collaborative approaches are important to continue the care of patients with untreated CVD, according to guidance from 15 North American cardiology societies. Read more

ACC: New module to collect data on CV complications of COVID-19

Using the National Cardiovascular Data Registry Chest Pain-MI and CathPCI registries, the American College of Cardiology will begin collecting data with the aim of discerning the relationship between the COVID-19 and heart disease. Read more